Brutalist Biotech
Max
3
|
5
|
10
|
20
items per feed.
Cutting-edge Biotech news: Presented the old-fashioned way.
Fierce Biotech
Epicrispr gene silencer is 1st drug to boost muscle in form of muscular dystrophy, biotech says
(18h)
Biogen ends Apellis research programs, cuts ‘small number’ of roles after $5.6B buyout
(19h)
Moderna enters in vivo CAR-T, granting autoimmune asset ‘007’ license to kill pathogenic cells
(20h)
Cardiac medtech HeartBeam drops CEO in restructuring aimed at global ECG platform push
(21h)
Chutes & Ladders—EMD Serono taps in new commercial strategy head
(1d)
The deal before the deal
(1d)
Fosun Pharma plots global push beyond oncology, fueled by multi-asset Alzheimer’s strategy
(1d)
Otsuka posts phase 3b ADHD trial win ahead of looming FDA approval decision
(1d)
Ionis bags $30M from Recordati for ex-US rights to near-approval rare disease prospect
(1d)
FDA drops blood pressure device enforcement against Whoop
(2d)
BioPharma Dive
At BIO, tension over China biotech deal regulation looms
(17h)
Alkermes’ incoming CEO has a plan to outplay Lilly and Takeda
(19h)
On second try, Acadia drug gets nod from European regulators
(19h)
Remix to go public in reverse merger with once high-flying Passage Bio
(1d)
FDA accepts Replimune filing; Merck KGaA drops $11B on life sciences services
(1d)
Antares gets $105M from Novartis for new cancer drugs
(1d)
Ionis, with new FDA nod, hits a ‘commercial inflection point’
(2d)
Investors pour $115M into RQ Bio in search of a preventive flu drug
(2d)
To Wall Street, psychedelics biotechs are more teammates than rivals
(2d)
Sangamo holds a bankruptcy sale; VCs back a China-linked Beam competitor
(2d)
Endpoints News
FDA approves Viridian eye drug, stoking competition with Amgen's Tepezza
(10h)
FDA advisory panels are back, with new meetings for Replimune, Capricor
(14h)
Akeso pushes back on ASCO questioning of lung cancer drug
(17h)
EU probes Sanofi for alleged smear campaign against rival flu vaccine
(17h)
Lycia raises $75M for food allergy and Graves’ disease
(18h)
EU regulators recommend revoking the marketing authorization for Amgen’s Tavneos
(19h)
How Epicrispr is using 'digital twins' to study a muscle disease therapy
(20h)
Michael Gilman retires as Arrakis CEO; Daniel Skovronsky joins Illumina's board of directors
(21h)
After buying Apellis for $5.6B, Biogen is cutting most of its pipeline work
(1d)
RTW’s Rod Wong on how China has (and hasn’t) changed his firm’s investments
(1d)
BioSpace
Capricor thrown for another loop as FDA sets adcomm for DMD cardiomyopathy therapy
(13h)
BIO 2026: Making biotech IPOs great again and the forgotten pharma antitrust review
(19h)
The hidden cost of FDA unpredictability
(19h)
Otsuka’s drug eases symptom burden, anxiety in ADHD as FDA verdict nears
(20h)
Moderna looks out to R&D ‘horizons’ as 2028 break-even goal looms
(20h)
Merck KgaA inks $11B Bio-Techne buyout to expand into cell therapy production
(21h)
BIO 2026: Forget dual track—biopharma deals are more complex than ever
(1d)
BIO 2026: FDA’s IND initiative is a step toward normalization after slipshod year
(1d)
The Golden Triangle and the gaps: Rethinking UK biotech
(1d)
Revolution’s second RAS blocker doubles chemo response rate in pancreatic cancer
(1d)
STAT News
BIO 2026: AI, federal policy impacts, and general vibes
(15h)
Up and down the ladder: The latest comings and goings
(17h)
988’s LGBTQ+ hotline to relaunch this year. But the group that helped start it might be excluded
(19h)
Embryo editing advances reignite ethical debates
(19h)
We’re reading about a bill to overhaul the 340B program, a new FDA commish candidate, and more
(19h)
European antitrust regulators probe Sanofi for allegedly disparaging a rival flu vaccine
(20h)
Supreme Court rules in weedkiller cancer case
(21h)
What is pulmonary hypertension and why would a new GLP-1 help?
(1d)
Joseph Fraumeni Jr., pioneering cancer genetics researcher, devoted his life to families like mine
(1d)
‘The Hot Zone’ led me to work with Ebola patients. Now I have mixed feelings about the book
(1d)
BioPharma Trend
Seven HealthTech Trends In Europe To Watch
(18h)
Self-Care Is Not a Product, It’s Critical Infrastructure: Why We Must Work Together to Make Health Systems Resilient.
(1w)
Ginkgo Datapoints, Tangible Scientific, and Inductive Bio launch ADME-One, a packaged ADME service for hit identification
(1mo)
AI Won't Replace Clinical Programmers. It Will Split Them Into Two Groups.
(1mo)
Novo Nordisk and OpenAI Team Up to Integrate AI from Discovery to Supply Chain
(2mo)
Life Biosciences Gets $80M as Cellular Rejuvenation Enters the Clinic
(2mo)
Jeito Closes €1B Fund, Europe's Largest Independent Biopharma Raise
(2mo)
Anthropic Pays $400M for an AI Biotech With Fewer Than Ten People
(2mo)
Epia Neuro Wants to Decode Brain's Movement Intentions After Stroke
(2mo)
Generare Raises €20M to Explore Uncharacterized Chemical Space from Microbial DNA
(2mo)
Drug Channels
BlinkRx Insights: The Questions Manufacturers Wish They Had Asked Before Selecting a Patient Services Partner
(22h)
Pharmacist Salaries and Employment in 2025: Retail Declines, Hospital Gains
(4d)
The Digital Front Door to Specialty Therapy May Not Be a Specialty Pharmacy
(1w)
Drug Channels News Roundup, Mid-June 2026: Biosimilar Development Barriers, Hospital Specialty Pharmacy Growth, Medicaid Incentives, Drug Pricing Tradeoffs, and the Prescription-Filling Process
(1w)
The IRA Fixed One Medicare Part D Distortion—But Patients Now Face New Tradeoffs
(1w)
The IRA Fixed One Medicare Part D Distortion—But Patients Now Face New Tradeoffs
(1w)
Minnesota’s 340B Hospitals Make One Billion More From 340B Than They Spend on Uncompensated Care (rerun)
(2w)
Minnesota’s 340B Hospitals Make One Billion More From 340B Than They Spend on Uncompensated Care (rerun)
(2w)
The Top 15 Specialty Pharmacies of 2025: PBM-Affiliated Pharmacies Dominate While Health Systems and Independents Gain Ground (rerun)
(2w)
The Top 15 Specialty Pharmacies of 2025: PBM-Affiliated Pharmacies Dominate While Health Systems and Independents Gain Ground (rerun)
(2w)
European Biotechnology Magazine
ProQR validates RNA editing platform and raises $59.2m
(1d)
Recordati secures ex-U.S. rights to Ionis’ Alexander disease therapy
(1d)
ADC Therapeutics cuts 17% of staff after safety setback
(2d)
Novartis signs up to $1.9bn deal to tap Antares’ undruggable-target engine
(2d)
Leyden Labs adds €40m for intranasal flu prevention
(2d)
RQ Bio raises $115m for long-acting flu antibody
(2d)
Thalia buys Sanmirna, becomes a clinical-stage RNA company
(3d)
Merck launches build-to-buy Saturnus Bio with $50m
(3d)
TRIMTECH extends seed round to $47M for protein degradation drugs
(3d)
Indivumed, ready to set sail to the clinic
(4d)
Drug Hunter
May 2026
(13h)
MRTX1719
(1d)
cleminorexton
(2d)
fluoxetine
(3d)
An ADC Primer for Medicinal Chemists
(4d)
CID-078
(1w)
zasocitinib (TAK-279/NDI-034858)
(1w)
Target- and Ligase-First Use of DCAF16 for TPD
(1w)
Topological Polar Surface Area Cheat Sheet
(1w)
irafamdastat (BMS-986368)
(2w)
Labiotech.EU
“It’s time to Act”: EU biotech to undergo major changes
(19h)
De-risking neurology drug development with better mouse models
(1d)
How human-first datasets are reshaping AI drug discovery
(2d)
Roche, a company built on oncology and diagnostics reinventing its pipeline
(2d)
Bronchiectasis treatment after brensocatib: where the field goes next
(3d)
8 of the most expensive drugs in biopharma: Unraveling the costliest medications
(4d)
The Naming Patterns Behind 12,000 Biotech Companies
(1w)
BIO International Convention 2026: practical advice from former Evotec CEO Werner Lanthaler
(1w)
Eight in vivo CAR T biotechs to follow closely
(1w)
Viral vector production: How CDMOs influence late-stage development success
(2w)
Bio IT World
The Spatial Biology Bottleneck: Why AI Models Fail on Complex Tissue & What Actually Fixes It
(1d)
Every Microbiome Tells a Changeable, Computable Story
(3d)
Notes from the Trenches: A Computational Biologist’s View of Drug Discovery’s Digital Revolution
(4d)
AI Readiness in Pharma – Getting the Foundation Right
(1w)
AI Readiness in Pharma – Getting the Foundation Right
(1w)
AI Readiness in Pharma – Getting the Foundation Right
(1w)
The Invisible Infrastructure: Bio-IT World Panel Warns of a Slow-Motion Crisis in Biomedical Data
(1w)
Microsoft, Ginkgo Collaborate to Demonstrate Lab-in-the-Loop Biology
(2w)
From Automation to Autonomy: How Agentic AI Is Redefining Biopharma’s Digital Workforce
(2w)
Navigating the Perilous Journey from Lab to Market
(2w)
GEN News
Backed by $165M, Bionyra Pharma Launches to Advance Inflammatory Disease Biologics
(13h)
Genome Editing at the Turning Point—Bringing CRISPR to Clinical Reality
(16h)
Intravesical CAR T-Cell Therapy Reduces Bladder Cancer Growth in Preclinical Model
(16h)
Nipah and Hendra Viruses: Antibody Cocktail Provides Complete Protection in Hamster Model
(17h)
Circio’s circVec and Tcelltech’s nanoSMAR Technologies Combined to Generate Nextgen In vivo CAR-T and TCR-T Cells
(20h)
AI Framework Surfaces New CAR T Target with Multi‑Cancer Potential
(1d)
Antibiotics Trigger Protein Sharing Among Bacteria, Aiding Persister Cells
(1d)
Merck KGaA to Acquire Bio-Techne for $11.3B, Expanding Life Science Tools Presence
(1d)
BIO 2026: FDA Leadership Confront Workforce Losses, China Competition in Drug Development
(1d)
InduPro Licenses Lonza’s Linker Payload Technologies and Bioconjugation Platforms
(1d)
Cure Today
Without Cancer I Am Practicing Self-Care
(1d)
FDA Approves Trodelvy Alone or With Keytruda for First-Line Triple-Negative Breast Cancer
(2d)
The Whole Person: How Susan Yaguda Is Redefining Cancer Care
(2d)
FDA Approves Ibrance Combo for Maintenance Treatment of HR-Positive, HER2-Positive Metastatic Breast Cancer
(2d)
Living With Cancer: What the Mariana Trench and Cancer Have in Common
(2d)
Nurse Navigator Provides Compassionate Care Beyond Diagnosis
(3d)
FDA Expands Tecelera Approval to Include Patients as Young as 12 With Advanced Synovial Sarcoma
(3d)
When a Routine Cancer Screening Stops Being Routine
(3d)
Called to Care: Dr. Jessica Scerbo on What It Really Means to Treat Children With Cancer
(4d)
Top 5 Takeaways From EHA 2026 That Patients Should Know
(4d)
Contract Pharma
Reducing Risk in Pharma Product Transfers
(15h)
Adragos Pharma Kawagoe, Towa Pharmaceutical Ink Strategic Supply Pact
(17h)
AI in Biologics CDMO Workflows: A BIO Conversation with Lonza
(17h)
The Friday Brief for June 26, 2026: BIO 2026 Recap
(18h)
Enzene Premieres Nex Partnership Program at BIO 2026
(1d)
Best Practices for Solving Complex Formulation Challenges While Maintaining Speed Through the Lifecycle
(1d)
From Potential to Practical at DIA 2026: A Three-Part Series on Unlocking AI’s Role in Modern Clinical Trials
(1d)
By the Numbers: Top 10 Pharma & Biopharma Companies
(1d)
Merck KGaA to Acquire Bio-Techne for $11.3B
(1d)
DDL Appoints Jennifer Riter as Vice President of Analytical Testing Services
(1d)
Pharma Times
Racura treats first patient in phase 1 HARNESS‑1 lung cancer trial
(2d)
NICE recommends MSD’s pembrolizumab for locally advanced cervical cancer
(2d)
Lundbeck to present new Vyepti and bocunebart data at EAN 2026
(2d)
Agomab outlines design of phase 2b NOV‑ERA study in fibrostenosing Crohn’s disease
(3d)
Pierre Fabre wins EC approval for Braftovi regimen in BRAFV600E‑mutant mCRC
(4d)
Cenrifki approved in EU for secondary progressive multiple sclerosis
(4d)
NICE backs daratumumab quadruplet for newly diagnosed transplant‑ineligible myeloma
(2w)
Anocca doses first patients with precision TCR‑T therapy
(2w)
Connecta launches phase 2a trial of neuroplasticity modulator
(2w)
Aquipta recommended by NICE for acute migraine treatment
(2w)
Medcity News
What Is AI Getting Right — and Wrong — in Healthcare’s Revenue Cycle?
(1w)
KFF: Insurer Participation in ACA Marketplaces Is Down
(1w)
FDA Reversal on uniQure Gene Therapy Is Another Sign of Renewed Regulatory Flexibility
(1w)
Combined GI Procedures Are Becoming Routine – AI Can Help Address the Gap in Upper GI Quality Standards
(1w)
The Human Behind the Machine: Why Healthcare Must Resist the Rush To Automate
(1w)
Leveraging Technology to Navigate the New Era of Continuous Organ Distribution
(1w)
InStride Raises $30M to Scale Pediatric Mental Health Support
(1w)
New Cancer Biotech Unveils $27M for Dual-Targeting Prostate Cancer Drug
(1w)
What’s Flowing Beneath the World Cup: How Verily’s Wastewater Monitoring Could Catch the Next Outbreak
(1w)
The FDA’s Bayesian Guidance Could Quietly Reshape Clinical Trial Design
(1w)
Chemical & Engineering News
Supreme Court sides with Bayer in landmark pesticide-labeling case
(13h)
A new method measures PFAS-based microplastics
(15h)
Policy Watch: HHS moves to keep more drug trials in the US
(16h)
Ancient Martian rocks preserve complex organic carbon
(17h)
Membrane-based separations for more efficient crude oil refining
(19h)
C&EN weekly chemistry news quiz, June 26
(21h)
Self-driving labs are changing how chemists work
(1d)
What happens when you edit an essential gene in human embryos?
(1d)
Merck KGaA to buy Bio-Techne for around $11 billion
(1d)
Chemistry in Pictures: Quantum carbenes
(1d)
The Pharma Letter
Why has the need in gMG become so severe, and how has understanding evolved?
(16h)
EC opens formal antitrust investigation on Sanofi
(16h)
June 2026 batch of EMA/CHMP recommendations
(16h)
Elixirgen and Nippon Shinyaku ink option agreement on DMD
(19h)
EC approves Inaqovi combination for AML patients ineligible for intensive chemotherapy
(19h)
Definium raises $805 million after positive Phase III depression data
(19h)
Menarini reports data from the Phase III SENTRY trial of selinexor
(21h)
NHS A&E testing finds 1,900 undiagnosed HIV cases
(22h)
Candel hires AstraZeneca executive to lead commercial plans
(22h)
NICE recommends MSD’s Keytruda for LAAC in adults
(23h)
Targeted Oncology
NCCN Guidelines Recommend ctDNA-MRD Testing in MIBC Care
(1d)
Emerging Evidence for Earlier Intervention in Low-Risk Polycythemia Vera
(2d)
Why Many Oncologists Still Reach for G-CSF Over Trilaciclib in ES-SCLC
(2d)
FDA Approves Sacituzumab Govitecan for First-Line TNBC Treatment
(2d)
KOMET-007: Bringing Menin Inhibition Into Frontline AML Care
(2d)
FDA Approves Palbociclib Plus Anti-HER2 and Endocrine Therapy as Maintenance in Breast Cancer
(2d)
Isa-VRd Sustains and Deepens MRD Negativity in Transplant-Ineligible Myeloma
(2d)
Dr Ahn: Exploring Treatment-Free Remissions With Pirtobrutinib in CLL
(2d)
Zanzalintinib Plus Atezolizumab Misses OS End Point in Liver Metastasis–Free mCRC Subgroup
(3d)
Florez Highlights Overlooked Needs of Young Patients, Women With Lung Cancer
(3d)
MedWatch
Hims & Hers poised to benefit as insurers pull back on weight-loss drug coverage
(20h)
Demant on track for best quarter since the turn of the millennium
(21h)
GN Hearing CFO to join Danish shipping company
(22h)
US biotech index hits record high, Danske Bank cites several drivers
(23h)
Removing gender and photos from applications led Gubra to gender equality in management
(23h)
Internal EU document: Biotech Act has only limited impact
(1d)
Pfizer cleared in lawsuit over illegal price-fixing
(1d)
Novo Nordisk saw slight decline in prescriptions for Wegovy tablets last week
(1d)
EIFO ready with historic investment in new European fund
(1d)
Eli Lilly to launch weight-loss drugs for Medicare patients starting July 1
(1d)
In The Pipeline
Speaking Up: Who Is, and Who Isn't
(11h)
Antibody-Drug Conjugates: Not Quite Worked Out Yet
(1d)
Here's a Ligand, Go Design a Protein
(2d)
Machine-Learning Mass Spec Data: Hmmm
(4d)
Covid-19 Vaccinations and the Heart
(2w)
Hydroxyl Radicals In Water Droplets? Doesn't Look Like It.
(2w)
A New Antibiotic Idea From An Old Source
(2w)
Insights Into Idiopathic Pulmonary Fibrosis
(2w)
Unusual Toxicity With a Protein Degrader Molecule
(3w)
The Causes of Long Covid
(3w)
Pharmaphorum
Sanofi faces EU investigation over flu shot marketing
(21h)
Moderna shows in vivo CAR-T hand in R&D update
(22h)
Obesity is rising fastest in young adults in England
(1d)
Merck buys life sciences firm Bio-techne in $11.3bn deal
(1d)
Hub-and-spoke firm Osanni raises $190m, and other financings
(1d)
Ibrance cleared in US for 'double-positive' breast cancer
(1d)
Tarek Samad takes on task of delivering on Lundbeck's RD
(1d)
NICE delivers more good news for cervical cancer patients
(1d)
Ionis' Tryngolza claims critical label expansion in US
(2d)
Lilly launches its LillyDirect sales channel in the UK
(2d)
Drug Discovery Weekly
Wegovy pill could help patients lose 17% body weight
(1w)
How AskBio is pioneering ‘transformative genetic therapies’ in Parkinson’s disease
(1w)
Webinar: Learn how to accelerate the early stages of drug discovery
(1w)
Therapy enables 89% survival rate in myeloma patients
(1w)
Ulcerative colitis treatment shows best-in-class potential
(1w)
UK patients to benefit from approval of weight loss tablet
(1w)
Vertex presents new data on Casgevy in children
(1w)
DDW Highlights: 16 June 2026
(1w)
LXR inverse agonist shows promise in liver disease
(1w)
Guide: One solution – from R&D, to QC
(1w)
HIT Consultant
KLAS Arch Collaborative Releases Clinician EHR Experience 2026 Impact Report
(18h)
Hera Raises $27M to Scale AI-Powered Senior Care Coordination
(18h)
ZS Impact Institute Releases 2026 Future of Health Report: AI and the Consumer-Led Care Revolution
(19h)
Hurone AI Licenses Mayo Clinic’s HOUSES Technology to Scale Personalized Cancer Navigation
(19h)
AMGA 2026 Survey: Provider Compensation Rises 4.3% as Medical Groups Face Sustainability Warning
(19h)
Beyond Chatbots: Agentic AI as the Operating System Transforming Patient Services
(1d)
Houston Methodist Partners with HealthLeap to Launch AI-Driven Clinical Screening Platform
(1d)
xCures Raises $46M to Turn Unstructured EHR Data Into Actionable Clinical Intelligence
(1d)
Upside Secures $20M to Scale AI-Driven Housing Stability Platform for Healthcare
(1d)
Innovaccer and AWS Announce Multi-Year Strategic Collaboration to Scale Agentic AI in Healthcare
(1d)
Insights: Pink Sheet
US Pushing Foreign Countries To Pay More For Drugs: Will It Help Americans?
(10h)
BsUFA IV: Money Can’t Buy Industry Reference Product Exclusivity Determinations
(12h)
US FDA Adcomm Will Review Formerly Rejected Capricor, Replimune Regenerative Medicines
(14h)
Trump Nominates Medicare Director, HHS Power Broker Chris Klomp For Deputy Secretary
(14h)
Pink Sheet Podcast: US FDA’s New Guidance On One-Trial Efficacy Standard And IND Reform Pilot
(16h)
Omeros To Fight Its EU Corner After EMA Rejects US-Approved Yartemlea
(16h)
MaaT Pharma Leans On Expert Panel To Highlight aGvHD ‘Clinical Reality’ After EMA Rejection
(16h)
CSL Faces EU Withdrawal Of Tavneos After EMA Finds Study Data Unreliable
(16h)
Eli Lilly’s Once-Weekly Diabetes Basal Insulin Onswik Wins EMA Nod
(17h)
Japan Plans $370bn In Public-Private Investment By 2040 To Boost Pharma
(1d)
BioXconomy
AI cannot fix oncology drug discovery when preclinical models fail to reflect patient tumor biology
(12h)
Saudi drug authority expands US partnerships
(18h)
Clinilabs partners with Rutgers clinical research training
(20h)
Boundless Bio merges with Serapha Bio in $230m deal
(21h)
UK government advisors recommend mAb for type I diabetes treatment
(22h)
RQ Bio raises $115m Series A to advance single-dose flu antibody program
(1d)
‘I'd like it to be our secret’: Why pharma execs are doing business in Korea
(2d)
The reimbursement roadblock: Why cell and gene therapies are struggling to reach patients
(2d)
CEPI provides outbreak modeling to fast-track Bundibugyo ebolavirus vaccine trials
(2d)
Osanni Bio reemerges with $190m Series B after three year build
(2d)
BioCentury
Immunic tests Nurr1 to push beyond MS’s inflammation ceiling
(7h)
House committee to vote on China investment and in-licensing restrictions
(9h)
Definium’s $805M offering leads follow-on quartet: Public Equity Report
(9h)
CHMP joins FDA in challenging Tavneos’ approval basis
(10h)
Upcoming FDA adcomms will test post-Makary independence
(11h)
RQ Bio raises $115M to advance long-acting antibody prophylaxis for flu: Venture Report
(1d)
Hengrui rising: Frank Jiang on building a global biotech
(1d)
Tryngolza expansion gives Ionis its first prevalent-market test
(1d)
NewCo boom picks up pace in 1H26
(1d)
Where TrialBlazer puts FDA ahead — and where China still leads
(2d)
SCRIP
Viridian’s Lumvoa Puts Pressure On Amgen’s Tepezza In TED
(9h)
BIO 2026: Deals Are Surging Even As Chinese Competition And MFN Concerns Linger
(10h)
Callio Makes The Case For Dual-Payload ADCs
(13h)
Pfizer Discontinues Vizimpro In US Amid Oncologist Preference Shift
(17h)
Encouraging Signs For Revolution’s Pancreatic Cancer Combinations
(17h)
Merck KGaA Doubles Down On Life Sciences With $11.3bn Bio-Techne Buyout
(19h)
Big Pharma Boards Move AI From Strategy Slide To Paycheck
(21h)
Ionis Inks Zilganersen Pact With Recordati To Zero In On US
(21h)
Pivotal Phase II Results Advance HUTCHMED’s Fanregratinib Towards China Approval In ICC
(23h)
Korean Pharma Joins Global AI Boom Amid State Support
(1d)